Advertisement

Topics

H7N9 Bird Flu Virus - Biotech, Pharma and Life Science Channel

09:41 EDT 24th May 2017 | BioPortfolio

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally been found to infect humans, no human infections with H7N9 viruses have been reported until recent reports from China.

News Articles [9 Associated News Articles listed on BioPortfolio]

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

-100% of subjects in 100 µg intramuscular (IM) cohort achieved HAI titers that are accepted correlate of seroprotection against seasonal flu- -mRNA-1440 safe and ...

EpiVax Signs First Commercial License for Tregitope Technology

PROVIDENCE, R.I., April 25, 2017 /PRNewswire/ -- Providence-based biotechnology company EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology to an undisclosed global pharma...

Even One Infected Chicken Could Have a Global Impact

LAUREL, Miss., March 23, 2017 /PRNewswire/ -- With the USDA's confirmation of Avian Influenza in southern Tennessee, Alabama, and now Kentucky, the virus has struck the United States for the four...

PrimeStore® Molecular Transport Medium Aiding Laboratories Tracking H7N9 Avian Influenza

BETHESDA, Md., March 22, 2017 /PRNewswire/ -- Longhorn Vaccines and Diagnostics LLC (LHNVD) today announced that government laboratories in Europe and Asia have increased use of PrimeStore® MTM for t...

Protein Sciences Gears Up to Combat Pandemic Influenza Due to Recent Outbreaks in China

MERIDEN, Conn., March 21, 2017 /PRNewswire/ -- In light of the growing concern over recent Avian Influenza outbreaks in China, Protein Sciences Corporation, maker of the highly effective Flublok® Inf...

Nanotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 17022017] Prices from USD $250

SummaryNanotherapeutics Inc Nanotherapeutics is a biopharmaceutical company that develops and manufactures biopharmaceutical products. The company's products include H5N1 Indonesia, river vaccine, H9N...

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016

LONDON, Jan. 30, 2017 /PRNewswire/ -- Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide In...

Nanotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryNanotherapeutics Inc Nanotherapeutics is a biopharmaceutical company that develops and manufactures biopharmaceutical products. The company's products include H5N1 Indonesia, river vaccine, H9N...

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2016 Prices from USD $2000

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infection...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine.

This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years o...

H7N9 Boost in Healthy Adults

The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 vaccine (non-adjuvanted). The subjects of the study will be individuals who previously partic...

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine ...

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

This is a Phase II randomized, partially-blinded, controlled trial in 360 (up to 600) males and females, 65 years of age and older, who are in good health and meet all eligibility criteria...

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Background:< TAB> - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe illness, even death. Vaccines are used to try to create resistance to such i...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility crit...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

A phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as s...

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

IFITM3, TLR3, and CD55 Genes SNPs and Cumulative Ge-netic Risks for Severe Outcomes in Chinese Patients with H7N9 / H1N1pdm09 Influenza.

We examined associations between SNPs (single-nucleotide-polymorphisms) of IFITM3, TLR3, and CD55 genes and influenza clinical outcomes in Chinese patients.

Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.

Since 2013, the outbreak or sporadic infection of a new reassortant H7N9 influenza virus in China has resulted in hundreds of deaths and thousands of illnesses. An H7N9 vaccine is urgently needed, as ...

A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines.

Influenza vaccines of H7N9 subtype are consistently less immunogenic in humans than vaccines developed for other subtypes. Although prior immunoinformatic analysis identified T-cell epitopes in H7 hem...

Correction: Influenza A H5N1 and H7N9 in China: A spatial risk analysis.

[This corrects the article DOI: 10.1371/journal.pone.0174980.].

Preliminary epidemiologic assessment of human infections with highly pathogenic avian influenza A(H5N6) virus, China.

Since 2014, 17 human cases of infection with the newly emerged highly pathogenic avian influenza A(H5N6) virus have been identified in China to date. The epidemiologic characteristics of laboratory-co...

Advancing new vaccines against pandemic influenza in low-resource countries.

With the support of the Biomedical Advanced Research and Development Authority (BARDA), PATH is working with governments and vaccine manufacturers to strengthen their influenza vaccine manufacturing c...

Human infections with recently-emerging highly pathogenic H7N9 avian influenza in China.

Influenza A H5N1 and H7N9 in China: A spatial risk analysis.

Zoonotic avian influenza poses a major risk to China, and other parts of the world. H5N1 has remained endemic in China and globally for nearly two decades, and in 2013, a novel zoonotic influenza A su...

Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017.

During March 2013-February 24, 2017, annual epidemics of avian influenza A(H7N9) in China resulted in 1,258 avian influenza A(H7N9) virus infections in humans being reported to the World Health Organi...

Human infection caused by an avian influenza A (H7N9) virus with a polybasic cleavage site in Taiwan, 2017.

Videos

None available.

Medical and Biotech [MESH] Definitions

A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.

Quick Search
Advertisement
 

Relevant Topics

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

review and buy H7N9 Bird Flu Virus market research data and corporate reports here

Channels Quicklinks